Treatment with dupilumab may help patients with uncontrolled, moderate to severe asthma achieve “clinical asthma remission.”

Patients with atopy may experience less severe outcomes when diagnosed with COVID-19.

Weekly dupilumab improved disease-specific health-related quality of life and symptom burden in adolescent and adult patients with eosinophilic esophagitis.

Patients with severe CRSwNP have worse health-related quality of life burden than the general population despite having a history of systemic corticosteroid and surgery, or comorbid asthma or nonsteroidal anti-inflammatory drug-exacerbated respiratory disease.

Researchers have developed a scoring system that assesses lower respiratory and extra-respiratory symptoms and better monitors aspirin-induced reaction severity in patients with aspirin-exacerbated respiratory disease.

Mepolizumab reduces disease symptoms in patients with chronic rhinosinusitis with nasal polyps, according to the results of a randomized, double-blind, multicenter study.

Patients with asthma who depend on oral corticosteroids (OCS) may be able to reduce the dependence or eliminate the use of OCS altogether with benralizumab.

The use of CREON2000A UV air irradiation system technology reduced asthma severity in children with mild to moderate asthma.

Berotralstat may reduce the use of on-demand medications in patients with hereditary angioedema (HAE) who were previously treated with prophylactic therapies.

Black/African American and Hispanic individuals compared with White/Caucasian individuals were found to be highly underrepresented in food allergy immunotherapy trials.

In patients with moderate to severe chronic rhinosinusitis with nasal polyposis, treatment with an Exhalation Delivery System With Fluticasone (EDS-FLU) is associated with improved sleep scores.

Patients with mild to moderate atopic dermatitis and comorbid asthma or allergic rhinitis treated with crisaborole had significantly higher treatment success rates compared with vehicle control.

Compared with the absence of asthma, the presence of asthma is associated with a comparable risk of hospitalization and use of mechanical ventilation, and a lower risk of mortality in patients with COVID-19.

A single dose of PHA-022121, an oral beta-2 antagonist, was associated with effective bradykinin-inhibiting concentrations within 15 minutes of administration in patients with hereditary angioedema.

Treatment with trimethoprim-sulfamethoxazole was associated with improvements in lung function and decreased visits to the emergency department among children with asthma.

Disease severity of both chronic obstructive pulmonary disease (COPD) and asthma may increase the risk of the development of severe coronavirus disease 2019 (COVID-19).

Treatment with omalizumab was associated with sleep improvements in patients with chronic rhinosinusitis with nasal polyps.

Budesonide oral suspension improved histologic, endoscopic, and both histologic and symptomatic outcomes in children with eosinophilic esophagitis compared with placebo.

Children with atopic dermatitis who were treated with dupilumab and topical corticosteroids showed improvements in treatment success compared with topical corticosteroids alone.

Researchers evaluated the potential predictive characteristics of eosinophilic esophagitis following IBD diagnosis in children.

Researchers studied subgroups of patients with uncontrolled asthma to determine if cardiovascular risk would affect their response to umeclidinium added to fluticasone furoate/vilanterol.

In patients with asthma, the use of inhaler electronic medication monitors with both rescue and controller inhalers is associated with higher adherence to these devices.

Active eosinophilic esophagitis appears to be associated with lower lung function and increased asthma severity in children with comorbid asthma.